TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a mixed outlook. While the company reaffirmed its revenue guidance and showed strong gross margins, there were concerns about increased losses and expenses. The Q&A revealed confidence in recovery from sales disruptions and successful commercial expansion. However, risks like FDA clearance delays and financial losses temper optimism. Overall, the positive aspects are balanced by the negatives, resulting in a neutral sentiment.
Key Financial Performance
Revenue for Q1 2026 $8.9 million, a decrease from $9.2 million in the prior year period. The lower revenues were due to the transition related to the expanded commercial organization.
Gross Margin for Q1 2026 86%, an increase from 84% in the prior year period. The improvement was driven by lower average unit cost on TriNav and continuous manufacturing improvement.
Research and Development Expenses for Q1 2026 $3.2 million, an increase from $3 million in the prior year period. The increase was driven by noncash stock-based compensation expense.
Sales and Marketing Expenses for Q1 2026 $7.4 million, an increase from $6.7 million in the prior year period. The increase reflects deliberate investment in expanding the commercial footprint, including head count, onboarding, expanded training, and territory development costs associated with the sales force expansion.
General and Administrative Expenses for Q1 2026 $5.4 million, an increase from $5.2 million in the prior year period. The increase was driven by higher noncash stock-based compensation expense.
Net Operating Loss for Q1 2026 $8.4 million, an increase from $7.3 million in the prior year period. The increase reflects lower revenue from the commercial expansion and a deliberate increase in sales and marketing investment associated with the commercial expansion.
Adjusted EBITDA Loss for Q1 2026 $5.8 million, an increase from $5.5 million in the first quarter of 2025. The increase reflects the same factors as the net operating loss.
Cash and Cash Equivalents as of March 31, 2026 $56.6 million, ensuring the company is fully funded for its strategic growth plan.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pressure-Enabled Drug Delivery (PEDD) technology: Landmark real-world evidence study published, demonstrating fewer complications, fewer hospitalizations, and approximately $7,700 per patient in cost avoidance. PEDD-treated patients showed better outcomes, including less fatigue, preserved immune function, and improved tumor targeting.
TriNav Advance: Next-generation device extending PEDD capability to small distal vessels via microcatheter. FDA clearance delayed by approximately 5 months, expected in the second half of 2026.
Commercial organization expansion: Significant expansion of sales and commercial operations, including new leadership and increased field footprint. This aims to deepen physician engagement and extend market reach.
New applications for PEDD: Expanding into uterine artery embolization, thyroid artery embolization, and genicular artery embolization, representing a U.S. addressable market of approximately $2.5 billion.
Revenue guidance: Revised 2026 revenue guidance to $54 million to $57 million due to lower Q1 revenues and delayed FDA clearance for TriNav Advance.
Clinical studies: 10 active studies across 24 clinical sites, generating data on over 400 TriNav-treated patients. Two new prospective trials and two large retrospective studies initiated.
Pancreatic cancer strategy: Advancing a novel pancreatic PEDD device and nelitolimod program through a partnership structure to address significant unmet needs in oncology.
Clinical evidence generation: Focused on generating differentiated clinical data to drive adoption and establish PEDD as a standard of care across multiple indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Impact from Commercial Expansion: The transition related to the expanded commercial organization led to lower revenues in Q1 2026 ($8.9 million compared to $9.2 million in the prior year). This reflects the cost of territory realignment, onboarding, and training, which disrupted sales productivity.
FDA Clearance Delay for TriNav Advance: The FDA review of TriNav Advance is running approximately 5 months past the 30-day MDUFA review goal. This delay has removed revenue expectations for the second half of 2026, impacting financial projections and delaying market entry for the next-generation device.
Sales Productivity Challenges: In 40% of territories, simultaneous modifications to rep-to-physician and rep-to-manager relationships disrupted execution and unit volume. This has created a temporary decline in sales productivity, expected to recover later in the year.
Increased Operating Costs: Deliberate investments in expanding the commercial footprint, including headcount, onboarding, training, and territory development, have increased sales and marketing expenses ($7.4 million compared to $6.7 million in the prior year).
Regulatory and Market Risks: The inherent unpredictability of FDA clearance timing for TriNav Advance poses risks to revenue forecasts and market strategy. Additionally, the delayed launch impacts the ability to capture incremental market opportunities.
Economic and Financial Risks: Net operating loss increased to $8.4 million in Q1 2026 (compared to $7.3 million in the prior year), driven by lower revenue and higher sales and marketing expenses. Adjusted EBITDA loss also increased to $5.8 million.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: TriSalus revised its full-year 2026 revenue guidance to a range of $54 million to $57 million. This revision accounts for lower Q1 revenues due to commercial expansion and delayed FDA clearance for the TriNav Advance device.
FDA Clearance and Product Launch: FDA review of the TriNav Advance device is delayed by approximately 5 months. Clearance is expected in the second half of 2026, with a prudent approach to forecasting the launch and market evaluation period.
Commercial Expansion: The company has significantly expanded its commercial organization, including new leadership and a larger field footprint, to support future growth. Sales productivity is expected to improve steadily throughout 2026.
Clinical Data and Studies: TriSalus is generating new clinical evidence with 10 active studies across 24 sites and plans to publish results from completed trials. Two new prospective trials, PRESSURE and PREDICTT, are set to begin enrollment in Q2 2026.
New Applications and Market Opportunities: The company is exploring new applications for its PEDD technology, including uterine artery embolization, thyroid artery embolization, and genicular artery embolization. These represent a U.S. addressable market of approximately $2.5 billion.
Pancreatic Cancer Program: TriSalus plans to deliver a consolidated Phase I readout for its nelitolimod program in early H2 2026. The company is also advancing its pancreatic PEDD device and broader pancreatic strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you quantify the disruption caused by the 40% of the sales force that was disrupted, and provide confidence in the recovery trajectory of the business?
A:60% of sales territories were not disrupted and performed as expected, indicating no fundamental change in demand or adoption. The 40% disruption was due to changes in rep-to-manager and rep-to-physician dynamics caused by growth and territory expansion. New reps were also brought in, causing temporary disruption. The company is confident in recovery, with the right talent and territory footprint now in place, expecting continuous ramp-up throughout the year.
Q:Has the sales organization achieved the doubling in size as previously discussed, and when will this expansion be complete?
A:The sales organization has slightly exceeded the doubling target due to the high level of talent attracted, supported by raised capital. The company now has the right footprint of management, clinical specialists, and reps to scale further, addressing a $2.5 billion market.
Q:What was the composition and size of the commercial organization before and after the expansion?
A:Specific numbers were not provided. Qualitatively, the organization expanded more than double in territories, improved the rep-to-manager ratio, and added an executive management level to engage with hospital systems and payers. The organization is now sized for 400 accounts across liver and new applications.
Q:What is the typical ramp time for a new sales rep, and how should revenue cadence for the year be considered?
A:The typical ramp time for a new rep is 6-9 months. The company expects month-over-month growth for the rest of the year, with meaningful progress in Q3 and Q4 as reps reach productivity. Q2 is expected to show marginal sequential gains, with a significant ramp in the second half of the year.
Q:Where will the new PEDD data have the most direct impact, and how will it resonate with physicians and institutions?
A:The PEDD data validates the clinical and economic benefits of the technology, resonating with both interventional radiologists and oncologists. It highlights the real-world effectiveness and cost-effectiveness of the platform, supporting its inclusion in NCCN guidelines. The data also shows no effect on lymphopenia, which is significant for combining embolization with immunotherapy regimens without disrupting treatment.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers regarding the composition and size of the commercial organization before and after the expansion, offering only qualitative insights instead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advance
FDA clearance
Number
PEDD TACE
Today
TriSalus patient
analysis
center PEDD
change
choice
clearance timing
cohort
complication
cost avoidance
design
evidence PEDD
evidence study
fatigue
field
gap
head
headline
immunotherapy
investigator trial
law statement
line PEDD
liver metastasis
lymphopenia
microcatheter
modality
month
phase
practice
publication
readout
relationship
review
scale
world evidence
year
TLSI Transcript
TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presented a mixed outlook. While the company reaffirmed its revenue guidance and showed strong gross margins, there were concerns about increased losses and expenses. The Q&A revealed confidence in recovery from sales disruptions and successful commercial expansion. However, risks like FDA clearance delays and financial losses temper optimism. Overall, the positive aspects are balanced by the negatives, resulting in a neutral sentiment.
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary highlights strong financial performance with improved operating and EBITDA losses, alongside a reaffirmed 50% revenue growth guidance. Product development and strategic investments in the TriNav platform, coupled with expanding clinical applications, suggest growth potential. The Q&A session reveals optimism in product expansion and market penetration, though management's reluctance to provide specific financial guidance tempers enthusiasm. Overall, the combination of positive revenue outlook, strategic expansions, and improved financial metrics signals a positive stock movement.
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals solid financial management, with improved cash flow and reduced operating losses. The company's commitment to a 50% growth target and strategic investments in new applications and products support a positive outlook. Despite management's reluctance to provide 2026 guidance, the market strategy and product development updates are favorable. The Q&A highlights robust feedback and growth in new applications, enhancing the sentiment. The positive aspects outweigh the lack of long-term guidance, suggesting a potential stock price increase in the short term.
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call highlighted strong financial performance with a 42% sales increase and a 50% growth guidance for 2025. Product innovations and successful reimbursement progress are positive indicators. Despite operating losses, improved EBITDA and cash position provide stability. The Q&A revealed positive market reception for new products and mapping technology, with strategic investments in sales expected to drive growth. However, uncertainties in partnership discussions and unclear timelines for nelitolimod present some risks. Overall, the positive financials, growth trajectory, and market reception outweigh the uncertainties, suggesting a positive stock price movement.
TLSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
